149 related articles for article (PubMed ID: 36913047)
21. Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification.
Jansen E; Hamisch C; Ruess D; Heiland DH; Goldbrunner R; Ruge MI; Schnell O; Grau SJ
J Neurooncol; 2019 Dec; 145(3):501-507. PubMed ID: 31621043
[TBL] [Abstract][Full Text] [Related]
22. Diffuse low grade glioma after the 2016 WHO update, seizure characteristics, imaging correlates and outcomes.
Roberts M; Northmore T; Shires J; Taylor P; Hayhurst C
Clin Neurol Neurosurg; 2018 Dec; 175():9-15. PubMed ID: 30292978
[TBL] [Abstract][Full Text] [Related]
23. Functional outcome after language mapping for insular World Health Organization Grade II gliomas in the dominant hemisphere: experience with 24 patients.
Duffau H; Moritz-Gasser S; Gatignol P
Neurosurg Focus; 2009 Aug; 27(2):E7. PubMed ID: 19645563
[TBL] [Abstract][Full Text] [Related]
24. Is there a risk of seizures in "preventive" awake surgery for incidental diffuse low-grade gliomas?
Lima GL; Duffau H
J Neurosurg; 2015 Jun; 122(6):1397-405. PubMed ID: 25723301
[TBL] [Abstract][Full Text] [Related]
25. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article.
Yordanova YN; Moritz-Gasser S; Duffau H
J Neurosurg; 2011 Aug; 115(2):232-9. PubMed ID: 21548750
[TBL] [Abstract][Full Text] [Related]
26. Recovery of long-term paresis following resection of WHO grade II gliomas infiltrating the pyramidal pathway.
Martino J; Caballero H; DE Lucas EM; DA Silva-Freitas R; Velasquez C; Gomez E; Vazquez-Bourgon J; Vázquez-Barquero A
J Neurosurg Sci; 2017 Feb; 61(1):88-96. PubMed ID: 27857035
[TBL] [Abstract][Full Text] [Related]
27. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Kleinberg LR; Weingart J; Burger P; Carson K; Grossman SA; Li K; Olivi A; Wharam MD; Brem H
Cancer Invest; 2004; 22(1):1-9. PubMed ID: 15069758
[TBL] [Abstract][Full Text] [Related]
28. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
[TBL] [Abstract][Full Text] [Related]
29. Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project.
Pala A; Nadji-Ohl M; Faust K; Rückriegel S; Roder C; von der Brelie C; Forster MT; Löbel F; Schommer S; Löhr M; Renovanz M; Grübel N; Rothenbacher D; König R; Engelke J; Schmitz B; Wirtz CR; Ringel F; Senft C; Rohde V; Tatagiba M; Ernestus RI; Vajkoczy P; Ganslandt O; Nagel G; Coburger J
J Neurol Surg A Cent Eur Neurosurg; 2020 Jan; 81(1):48-57. PubMed ID: 31550737
[TBL] [Abstract][Full Text] [Related]
30. Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.
Motomura K; Chalise L; Ohka F; Aoki K; Tanahashi K; Hirano M; Nishikawa T; Yamaguchi J; Shimizu H; Wakabayashi T; Saito R
J Neurooncol; 2021 Jun; 153(2):361-372. PubMed ID: 34009509
[TBL] [Abstract][Full Text] [Related]
31. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
32. Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.
Franceschi E; Tosoni A; Bartolini S; Minichillo S; Mura A; Asioli S; Bartolini D; Gardiman M; Gessi M; Ghimenton C; Giangaspero F; Lanza G; Marucci G; Novello M; Silini EM; Zunarelli E; Paccapelo A; Brandes AA
Eur J Cancer; 2020 Sep; 137():10-17. PubMed ID: 32721633
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Performance of [
Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
[TBL] [Abstract][Full Text] [Related]
34. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Blonski M; Pallud J; Gozé C; Mandonnet E; Rigau V; Bauchet L; Fabbro M; Beauchesne P; Baron MH; Fontaine D; Peruzzi P; Darlix A; Duffau H; Taillandier L
J Neurooncol; 2013 Jun; 113(2):267-75. PubMed ID: 23479036
[TBL] [Abstract][Full Text] [Related]
36. Impact of Intraoperative Magnetic Resonance Imaging and Other Factors on Surgical Outcomes for Newly Diagnosed Grade II Astrocytomas and Oligodendrogliomas: A Multicenter Study.
Yahanda AT; Patel B; Shah AS; Cahill DP; Sutherland G; Honeycutt J; Jensen RL; Rich KM; Dowling JL; Limbrick DD; Dacey RG; Kim AH; Leuthardt EC; Dunn GP; Zipfel GJ; Leonard JR; Smyth MD; Shah MV; Abram SR; Evans J; Chicoine MR
Neurosurgery; 2020 Dec; 88(1):63-73. PubMed ID: 32717067
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant intraarterial chemotherapy with nimustine in the management of World Health Organization Grade IV gliomas of the brain. Experience at the Department of Neurosurgery of Düsseldorf University.
Roosen N; Kiwit JC; Lins E; Schirmer M; Bock WJ
Cancer; 1989 Nov; 64(10):1984-94. PubMed ID: 2553234
[TBL] [Abstract][Full Text] [Related]
38. Perioperative seizure in patients with glioma is associated with longer hospitalization, higher readmission, and decreased overall survival.
Dewan MC; White-Dzuro GA; Brinson PR; Thompson RC; Chambless LB
J Neurosurg; 2016 Oct; 125(4):1033-1041. PubMed ID: 26894454
[TBL] [Abstract][Full Text] [Related]
39. Accelerated progression of IDH mutant glioma after first recurrence.
Miller JJ; Loebel F; Juratli TA; Tummala SS; Williams EA; Batchelor TT; Arrillaga-Romany I; Cahill DP
Neuro Oncol; 2019 May; 21(5):669-677. PubMed ID: 30668823
[TBL] [Abstract][Full Text] [Related]
40. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
